Business description: Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.

Number of employees: 18

Sales by Activity: Cardiol Therapeutics Inc.

Fiscal Period: December 2021 (CAD) 2022 (CAD) 2023 (CAD) 2024 (CAD) 2025 (CAD)

Pharmaceuticals

78.76K - - - -

Geographical breakdown of sales: Cardiol Therapeutics Inc.

Fiscal Period: December 2021 (CAD) 2022 (CAD) 2023 (CAD) 2024 (CAD) 2025 (CAD)

Canada

78.76K - - - -

Executive Committee: Cardiol Therapeutics Inc.

Manager TitleAgeSince
Chief Executive Officer - 18/01/2017
Director of Finance/CFO - 15/08/2018
Chief Operating Officer - 02/12/2020
Chief Tech/Sci/R&D Officer 64 28/03/2021
Corporate Officer/Principal - 31/12/2021

Composition of the Board of Directors: Cardiol Therapeutics Inc.

Director TitleAgeSince
Director/Board Member - 14/12/2017
Director/Board Member - 18/01/2017
Chairman - 06/07/2021
Director/Board Member - 18/05/2022
Director/Board Member 59 02/12/2019
Director/Board Member 56 14/03/2022
Director/Board Member 54 18/05/2022
Director/Board Member 65 27/05/2025

Shareholders: Cardiol Therapeutics Inc.

NameStocks%Valuation
MM Asset Management, Inc.
12.93 %
15,598,560 12.93 % 26 M $
MMCAP International Inc. SPC
12.93 %
15,598,560 12.93 % 26 M $
Tejara Capital Ltd.
5.29 %
6,382,551 5.29 % 11 M $
Tejara Capital Ltd.
4.238 %
5,113,822 4.238 % 8 M $
Ikarian Capital LLC
2.756 %
3,325,000 2.756 % 6 M $

Company details: Cardiol Therapeutics Inc.

Cardiol Therapeutics, Inc.

2265 Upper Middle Road East

L6H 0G5, Oakville

+289 910 0850

http://www.cardiolrx.com
address Cardiol Therapeutics Inc.(CRDL)

Other Biotechnology & Medical Research

Change 5-day change 1-year change 3-year change Capi.($)
-2.41%+1.89%+5.88%+39.66% 136M
-0.62%-1.87%+46.31%+56.99% 63.77B
+0.35%+3.20%+14.92%+84.55% 56.37B
+0.53%+1.96%+15.37%+106.81% 54.62B
-2.81%-4.31%+23.50%+50.90% 44.06B
-0.33%-1.93%+20.15%+98.45% 42.11B
+0.55%+2.31%+224.97%+942.56% 41B
+3.27%+47.96%+112.67%+96.48% 34.92B
+1.22%-1.44%+14.89%+47.15% 32.82B
+0.89%+20.55%-42.03%+373.03% 24.7B
Average +0.06%+6.97%+43.66%+189.66% 39.45B
Weighted average by Cap. +0.18%+5.44%+48.49%+186.08%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Cardiol Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.620CAD
Average target price
7.000CAD
Spread / Average Target
+332.10%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cardiol Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. CRDL Stock
  4. Company Cardiol Therapeutics Inc.